Malondialdehyde-Modified Low-Density Lipoprotein as a Predictor of Major Adverse Limb Events after Endovascular Therapy in Patients with Lower Extremity Arterial Disease-Reference-Cited by-同舟云学术

Malondialdehyde-Modified Low-Density Lipoprotein as a Predictor of Major Adverse Limb Events after Endovascular Therapy in Patients with Lower Extremity Arterial Disease

Published:2023-11-01 Issue:11 Volume:30 Page:1612-1621
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Yokoi Masashi¹,Ito Tsuyoshi¹,Kawada Yu¹,Mizoguchi Tatsuya¹,Yamamoto Junki¹,Mori Kento¹,Nakasuka Kosuke¹,Kikuchi Shohei¹,Fujita Hiroshi¹,Kitada Shuichi¹,Goto Toshihiko¹,Seo Yoshihiro¹

Affiliation:

1. Department of Cardiology, Nagoya City University Graduate School of Medical Sciences

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/30/11/30_64091/_pdf

Reference25 articles.

1. 1) Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, McDermott MM, Misra S, Ujueta F; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation, 2021; 144: e171-e191

2. 2) Stavroulakis K, Torsello G, Bosiers M, Argyriou A, Tsilimparis N, Bisdas T. 2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions. JACC Cardiovasc Interv, 2021; 14: 692-701

3. 3) Suzuki K, Ueshima D, Higashitani M, Yamauchi Y, Hozawa K, Hayakawa N, Tobita K, Ogata K, Ohmine T, Nakamura M. Two-year results of endovascular therapy for femoropopliteal artery disease in Japan during the introduction of drug-eluting devices. Cardiovasc Interv Ther, 2022; 10.1007/s12928-022-00873-z

4. 4) Kim J, Park TK, Choi KH, Choi D, Ko YG, Lee JH, Yoon CH, Chae IH, Yu CW, Min PK, Lee SW, Lee SR, Koh YS, Choi SH; Korean Vascular Intervention Society (K-VIS) Endovascular therapy in Lower Limb Artery diseases (ELLA) Registry Investigators. Different association between renal dysfunction and clinical outcomes according to the presence of diabetes in patients undergoing endovascular treatment for peripheral artery disease. J Vasc Surg, 2020; 71: 132-140.e1

5. 5) Stone PA, Schlarb H, Campbell JE, Williams D, Thompson SN, John M, Campbell JR, AbuRahma AF. C-reactive protein and brain natriuretic peptide as predictors of adverse events after lower extremity endovascular revascularization. J Vasc Surg, 2014; 60: 652-660